U.S. Women Health Laboratory Testing Market - A Region-Wise Analysis: Focus on U.S. Women Health Laboratory Testing Market - Analysis and Forecast, 2022-2030
U.S. Women Health Laboratory Testing Market Industry Overview
The U.S. women health laboratory testing market was valued at $72.8 billion in 2021 and is anticipated to reach $106.8 billion by 2030, witnessing a CAGR of 4.30% during the forecast period 2022-2030. The market is driven by factors such as the increase in the prevalence of infectious diseases and cancer in women, rising awareness regarding women health-related tests, the rising average maternal age leading to increased risk of fetal chromosomal aneuploidies, and the upsurge in reproductive health problems leading to increased demand for laboratory testing in women.
Market Lifecycle Stage
The U.S. women health laboratory testing market is in the developed phase. The advancements in diagnostic technologies including applications of genetic testing in women's health and the significant number of mergers and acquisitions of companies to attain a better market share are some of the major opportunities in the U.S. women health laboratory testing market.
Market Segmentation:
Segmentation 1: by Hereditary Cancer
- Breast Cancer
- Cervical Cancer
- Ovarian Cancer
Segmentation 2: by Prenatal Screening and Diagnostic Testing
- Non-Invasive Prenatal Testing (NIPT)
- Maternal Serum Screening (MSS)
- Prenatal Diagnostic Testing
Segmentation 3: by Reproductive Health and Infectious Diseases
- Pregnancy and Ovulation Testing
- HPV Testing
- PAP Smear Testing
- HIV Testing
- CT/NG Testing
- Preimplantation Genetic Testing (PGT)
- Sexually Transmitted Infections
- Herpes Simplex Virus (HSV)
- Hepatitis
- Vaginal Infections
Segmentation 4: by Region
- Northeast Region
- Midwest Region
- South Region
- West Region
Recent Developments in the U.S. Women Health Laboratory Testing Market
- In November 2022, Roche Holdings launched its Cobas 5800, a new molecular diagnostic system to expand access to PCR testing in the U.S. The system can assist in the diagnosis of Infectious diseases, such as HIV, Hepatitis, transplant-associated viral illnesses, and respiratory and STIs.
- In February 2022, the Laboratory Corporation of America Holdings established a strategic partnership with Ascension to expand its testing capabilities.
- In January 2022, Yourgene announced that it has signed a strategic partnership agreement with EKF Diagnostics Holdings plc a point-of-care business with accredited laboratory testing capabilities in the U.S.
- In November 2022, Myriad Genetics announced that it has acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests.
- In August 2022, Natera, Inc. announced that the company has proactively filed a pre-submission to the FDA for its Panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process.
- In August 2021, the Laboratory Corporation of America Holdings acquired Ovia Health, to extend its leadership in women’s health.
- In August 2021, Myriad Genetics expanded access to genetic testing by launching a new version of its market-leading MyRisk Hereditary Cancer Test
The following are the drivers for the U.S. Women Health Laboratory Testing Market:
- Increase in the Prevalence of Infectious Diseases and Cancer in Women Leads to Increased Demand for Diagnosis
- Rising Awareness Regarding Women Health-Related Tests
- Rising Average Maternal Age Leading to Increasing Risk of Fetal Chromosomal Aneuploidies
- Upsurge in Reproductive Health Problems Leads to Increased Demand for Laboratory Testing in Women
- Stringent Regulatory Guidelines Related to Laboratory Testing Hindering the Market Growth in the U.S.
- Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the U.S.
Segments: The different segment of the report helps the reader understand the different type of laboratory tests/services for women's health available in the market. Moreover, the study provides the reader with a detailed understanding of tests/services that fall under the different segments, which are hereditary cancer, carrier screening, prenatal screening, and diagnostic testing, reproductive health and infectious diseases, and obstetrics and gynecology.
Growth/Marketing Strategy: The U.S. women health laboratory testing market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, merger and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been regulatory and legal activities to strengthen the position of their product in the U.S. market. For instance, in October 2019, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic for Treatment with Zejula in Late-line Ovarian Cancer.
*PDF email from publisher allows for 1-3 users, with permission to print*
- 1 Markets
- 1.1 U.S. Market Outlook
- 1.1.1 Product Definition
- 1.1.2 Inclusion and Exclusion Criteria
- 1.2 Business Dynamics
- 1.2.1 Impact Analysis
- 1.2.2 Business Drivers
- 1.2.2.1 Increase in the Prevalence of Infectious Diseases and Cancer in Women Leading to Increased Demand for Laboratory Diagnostics
- 1.2.2.2 Rising Awareness Regarding Women Health-Related Tests
- 1.2.2.3 Rising Average Maternal Age Leading to Increasing Risk of Fetal Chromosomal Aneuploidies
- 1.2.2.4 Upsurge in Reproductive Health Problems Leading to Increased Demand for Laboratory Testing in Women
- 1.2.3 Business Restraints
- 1.2.3.1 Stringent Regulatory Guidelines Related to Laboratory Testing Hindering the Market Growth in the U.S.
- 1.2.3.2 Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the U.S.
- 1.2.4 Business Opportunities
- 1.2.4.1 Advancement in Diagnostic Technologies, including Applications of Genetic Testing in Women's Health
- 1.2.4.2 Healthcare Disparities in the Rural Counties of the U.S.
- 1.2.4.3 Gap in Healthcare for Women of Reproductive Age with Psychological Distress
- 1.2.4.4 Significant Number of Mergers and Acquisitions by Companies to Attain a Better Market Share
- 2 U.S. Women Health Laboratory Testing Market (by Hereditary Cancer )
- 2.1 Overview
- 2.2 Breast Cancer
- 2.2.1 Epidemiology
- 2.2.2 Testing Market
- 2.2.3 Testing Market (by Region)
- 2.2.3.1 Northeast Region (by State)
- 2.2.3.2 Midwest Region (by State)
- 2.2.3.3 South Region (by State)
- 2.2.3.4 West Region (by State)
- 2.3 Cervical Cancer
- 2.3.1 Epidemiology
- 2.3.2 Testing Market
- 2.3.3 Testing Market (by Region)
- 2.3.3.1 Northeast Region (by State)
- 2.3.3.2 Midwest Region (by State)
- 2.3.3.3 South Region (by State)
- 2.3.3.4 West Region (by State)
- 2.4 Ovarian Cancer
- 2.4.1 Epidemiology
- 2.4.2 Testing Market
- 2.4.3 Testing Market (by Region)
- 2.4.3.1 Northeast Region (by State)
- 2.4.3.2 Midwest Region (by State)
- 2.4.3.3 South Region (by State)
- 2.4.3.4 West Region (by State)
- 3 U.S. Women Health Laboratory Testing Market (by Carrier Screening)
- 3.1 Overview
- 3.1.1 Testing Market
- 3.1.2 Testing Market (by Region)
- 3.1.2.1 Northeast Region (by State)
- 3.1.2.2 Midwest Region (by State)
- 3.1.2.3 South Region (by State)
- 3.1.2.4 West Region (by State)
- 4 U.S. Women Health Laboratory Testing Market (by Prenatal Screening and Diagnostic Testing)
- 4.1 Overview
- 4.2 Non-Invasive Prenatal Testing (NIPT)
- 4.2.1 Testing Market
- 4.2.2 Testing Market (by Region)
- 4.2.2.1 Northeast Region (by State)
- 4.2.2.2 Midwest Region (by State)
- 4.2.2.3 South Region (by State)
- 4.2.2.4 West Region (by State)
- 4.3 Maternal Serum Screening (MSS)
- 4.3.1 Testing Market
- 4.3.2 Testing Market (by Region)
- 4.3.2.1 Northeast Region (by State)
- 4.3.2.2 Midwest Region (by State)
- 4.3.2.3 South Region (by State)
- 4.3.2.4 West Region (by State)
- 4.4 Prenatal Diagnostic Testing
- 4.4.1 Testing Market
- 4.4.2 Testing Market (by Region)
- 4.4.2.1 Northeast Region (by State)
- 4.4.2.2 Midwest Region (by State)
- 4.4.2.3 South Region (by State)
- 4.4.2.4 West Region (by State)
- 5 U.S. Women Health Laboratory Testing Market (by Reproductive Health and Infectious Diseases)
- 5.1 Overview
- 5.2 Pregnancy and Ovulation Testing
- 5.2.1 Testing Market
- 5.2.2 Testing Market (by Region)
- 5.2.2.1 Northeast Region (by State)
- 5.2.2.2 Midwest Region (by State)
- 5.2.2.3 South Region (by State)
- 5.2.2.4 West Region (by State)
- 5.3 HPV Testing
- 5.3.1 Testing Market
- 5.3.2 Testing Market (by Region)
- 5.3.2.1 Northeast Region (by State)
- 5.3.2.2 Midwest Region (by State)
- 5.3.2.3 South Region (by State)
- 5.3.2.4 West Region (by State)
- 5.4 PAP Smear Testing
- 5.4.1 Testing Market
- 5.4.2 Testing Market (by Region)
- 5.4.2.1 Northeast Region (by State)
- 5.4.2.2 Midwest Region (by State)
- 5.4.2.3 South Region (by State)
- 5.4.2.4 West Region (by State)
- 5.5 HIV Testing
- 5.5.1 Testing Market
- 5.5.2 Testing Market (by Region)
- 5.5.2.1 Northeast Region (by State)
- 5.5.2.2 Midwest Region (by State)
- 5.5.2.3 South Region (by State)
- 5.5.2.4 West Region (by State)
- 5.6 CT/NG Testing
- 5.6.1 Testing Market
- 5.6.2 Testing Market (by Region)
- 5.6.2.1 Northeast Region (by State)
- 5.6.2.2 Midwest Region (by State)
- 5.6.2.3 South Region (by State)
- 5.6.2.4 West Region (by State)
- 5.7 Preimplantation Genetic Testing (PGT)
- 5.7.1 Testing Market
- 5.7.2 Testing Market (by Region)
- 5.7.2.1 Northeast Region (by State)
- 5.7.2.2 Midwest Region (by State)
- 5.7.2.3 South Region (by State)
- 5.7.2.4 West Region (by State)
- 5.8 Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia)
- 5.8.1 Testing Market
- 5.8.2 Testing Market (by Region)
- 5.8.2.1 Northeast Region (by State)
- 5.8.2.2 Midwest Region (by State)
- 5.8.2.3 South Region (by State)
- 5.8.2.4 West Region (by State)
- 5.9 Herpes Simplex Virus (HSV)
- 5.9.1 Testing Market
- 5.9.2 Testing Market (by Region)
- 5.9.2.1 Northeast Region (by State)
- 5.9.2.2 Midwest Region (by State)
- 5.9.2.3 South Region (by State)
- 5.9.2.4 West Region (by State)
- 5.1 Hepatitis
- 5.10.1 Testing Market
- 5.10.2 Testing Market (by Region)
- 5.10.2.1 Northeast Region (by State)
- 5.10.2.2 Midwest Region (by State)
- 5.10.2.3 South Region (by State)
- 5.10.2.4 West Region (by State)
- 5.11 Vaginal Infections
- 5.11.1 Testing Market
- 5.11.2 Testing Market (by Region)
- 5.11.2.1 Northeast Region (by State)
- 5.11.2.2 Midwest Region (by State)
- 5.11.2.3 South Region (by State)
- 5.11.2.4 West Region (by State)
- 6 U.S. Women Health Laboratory Testing Market (by Obstetrics and Gynaecology)
- 6.1 Overview
- 6.1.1 Testing Market (by Region)
- 6.1.1.1 Northeast Region (by State)
- 6.1.1.2 Midwest Region (by State)
- 6.1.1.3 South Region (by State)
- 6.1.1.4 West Region (by State)
- List of Figures
- Figure 1: Percentage of Women with Two or More Chronic Conditions, Aged 18-64 Years (by Country)
- Figure 2: U.S. Women Health Laboratory Testing Market, $Billion, 2021-2030
- Figure 3: U.S. Women Health Laboratory Testing Market (by Test Type), $Billion, 2021 and 2030
- Figure 4: U.S. Women Health Laboratory Testing Market (by Region), $Billion, 2021-2030
- Figure 5: U.S. Women Health Laboratory Testing Market, Impact Analysis
- Figure 6: U.S. Women Health Laboratory Testing Market, Key Development Analysis, January 2019-October 2022
- Figure 7: U.S. Women Health Laboratory Testing Market Segmentation
- Figure 8: U.S. Women Health Laboratory Testing Market: Research Methodology
- Figure 9: Primary Research Sources
- Figure 10: Secondary Research
- Figure 11: Data Triangulation
- Figure 12: Assumptions and Limitations
- Figure 13: U.S. Women Laboratory Testing Market, Impact Analysis
- Figure 14: Gonorrhea and Chlamydia: Rates of Reported Cases by Age Group in Women, 2020
- Figure 15: Estimated Incidence and Mortality of Cancer in Women in the U.S. (2020, 2025, 2030, 2035, and 2040)
- Figure 16: Rate of Miscarriages with Increasing Maternal Age
- Figure 17: U.S. Fertility Rates (by Total Births Per Women), 1960-2020
- Figure 18: U.S. Women Health Laboratory Testing Market (by Hereditary Cancer)
- Figure 19: Incidence and Mortality of Breast Cancer in the U.S. (2020, 2025, 2030, 2035, and 2040)
- Figure 20: Rate of New Breast Cancer Cases in the U.S. Per 100,000 Women Population (by State)
- Figure 21: U.S. Breast Cancer Market, $Million, 2021-2030
- Figure 22: U.S. Breast Cancer Market (by Region), TAM, $Million, 2021-2030
- Figure 23: U.S. Breast Cancer Market (by Region), SAM, $Million, 2021-2030
- Figure 24: U.S. Breast Cancer Market (by Region), SOM, $Million, 2021-2030
- Figure 25: Northeast Region Breast Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 26: Northeast Region Breast Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 27: Northeast Region Breast Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 28: Midwest Region Breast Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 29: Midwest Region Breast Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 30: Midwest Region Breast Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 31: South Region Breast Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 32: South Region Breast Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 33: South Region Breast Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 34: West Region Breast Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 35: West Region Breast Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 36: West Region Breast Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 37: Estimated Incidence and Mortality of Cervical Cancer in the U.S. (2020, 2025, 2030, 2035, and 2040)
- Figure 38: Rate of New Cervical Cancer Cases in the U.S. Per 100,000 Women Population (by State), 2019
- Figure 39: U.S. Cervical Cancer Market, $Million, 2021-2030
- Figure 40: U.S. Cervical Cancer Market (by Region), TAM, $Million, 2021-2030
- Figure 41: U.S. Cervical Cancer Market (by Region), SAM, $Million, 2021-2030
- Figure 42: U.S. Cervical Cancer Market (by Region), SOM, $Million, 2021-2030
- Figure 43: Northeast Region Cervical Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 44: Northeast Region Cervical Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 45: Northeast Region Cervical Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 46: Midwest Region Cervical Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 47: Midwest Region Cervical Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 48: Midwest Region Cervical Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 49: South Region Cervical Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 50: South Region Cervical Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 51: South Region Cervical Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 52: West Region Cervical Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 53: South Region Cervical Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 54: South Region Cervical Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 55: Incidence and Mortality of Ovarian Cancer in the U.S. (2020, 2025, 2030, 2035, and 2040)
- Figure 56: Ovarian Cancer Cases (by State), 2019
- Figure 57: U.S. Ovarian Cancer Market, $Million, 2021-2030
- Figure 58: U.S. Ovarian Cancer Market (by Region), TAM, $Million, 2021-2030
- Figure 59: U.S. Ovarian Cancer Market (by Region), SAM, $Million, 2021-2030
- Figure 60: U.S. Ovarian Cancer Market (by Region), SOM, $Million, 2021-2030
- Figure 61: Northeast Region Ovarian Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 62: Northeast Region Ovarian Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 63: Northeast Region Ovarian Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 64: Midwest Region Ovarian Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 65: Midwest Region Ovarian Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 66: Midwest Region Ovarian Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 67: South Region Ovarian Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 68: South Region Ovarian Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 69: South Region Ovarian Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 70: West Region Ovarian Cancer Market (by State), TAM, $Million, 2021-2030
- Figure 71: West Region Ovarian Cancer Market (by State), SAM, $Million, 2021-2030
- Figure 72: West Region Ovarian Cancer Market (by State), SOM, $Million, 2021-2030
- Figure 73: U.S. Carrier Screening Market, $Million, 2021-2030
- Figure 74: U.S. Carrier Screening Market (by Region), TAM, $Million, 2021-2030
- Figure 75: U.S. Carrier Screening Market (by Region), SAM, $Million, 2021-2030
- Figure 76: U.S. Carrier Screening Market (by Region), SOM, $Million, 2021-2030
- Figure 77: Northeast Region Carrier Screening Market (by State), TAM, $Million, 2021-2030
- Figure 78: Northeast Region Carrier Screening Market (by State), SAM, $Million, 2021-2030
- Figure 79: Northeast Region Carrier Screening Market (by State), SOM, $Million, 2021-2030
- Figure 80: Midwest Region Carrier Screening Market (by State), TAM, $Million, 2021-2030
- Figure 81: Midwest Region Carrier Screening Market (by State), SAM, $Million, 2021-2030
- Figure 82: Midwest Region Carrier Screening Market (by State), SOM, $Million, 2021-2030
- Figure 83: South Region Carrier Screening Market (by State), TAM, $Million, 2021-2030
- Figure 84: South Region Carrier Screening Market (by State), SAM, $Million, 2021-2030
- Figure 85: South Region Carrier Screening Market (by State), SOM, $Million, 2021-2030
- Figure 86: West Region Carrier Screening Market (by State), TAM, $Million, 2021-2030
- Figure 87: West Region Carrier Screening Market (by State), SAM, $Million, 2021-2030
- Figure 88: West Region Carrier Screening Market (by State), SOM, $Million, 2021-2030
- Figure 89: U.S. Women Health Laboratory Testing Market (by Prenatal Screening and Diagnostic Testing)
- Figure 90: U.S. Non-Invasive Prenatal Testing Market, $Million, 2021-2030
- Figure 91: U.S. Non-Invasive Prenatal Testing Market (by Region), TAM, $Million, 2021-2030
- Figure 92: U.S. Non-Invasive Prenatal Testing Market (by Region), SAM, $Million, 2021-2030
- Figure 93: U.S. Non-Invasive Prenatal Testing Market (by Region), SOM, $Million, 2021-2030
- Figure 94: Northeast Region Non-Invasive Prenatal Testing Market (by State), TAM, $Million, 2021-2030
- Figure 95: Northeast Region Non-Invasive Prenatal Testing Market (by State), SAM, $Million, 2021-2030
- Figure 96: Northeast Region Non-Invasive Prenatal Testing Market (by State), SOM, $Million, 2021-2030
- Figure 97: Midwest Region Non-Invasive Prenatal Testing Market (by State), TAM, $Million, 2021-2030
- Figure 98: Midwest Region Non-Invasive Prenatal Testing Market (by State), SAM, $Million, 2021-2030
- Figure 99: Midwest Region Non-Invasive Prenatal Testing Market (by State), SOM, $Million, 2021-2030
- Figure 100: South Region Non-Invasive Prenatal Testing Market (by State), TAM, $Million, 2021-2030
- Figure 101: South Region Non-Invasive Prenatal Testing Market (by State), SAM, $Million, 2021-2030
- Figure 102: South Region Non-Invasive Prenatal Testing Market (by State), SOM, $Million, 2021-2030
- Figure 103: West Region Non-Invasive Prenatal Testing Market (by State), TAM, $Million, 2021-2030
- Figure 104: West Region Non-Invasive Prenatal Testing Market (by State), SAM, $Million, 2021-2030
- Figure 105: West Region Non-Invasive Prenatal Testing Market (by State), SOM, $Million, 2021-2030
- Figure 106: U.S. Maternal Serum Screening Market, $Million, 2021-2030
- Figure 107: U.S. Maternal Serum Screening Market (by Region), TAM, $Million, 2021-2030
- Figure 108: U.S. Maternal Serum Screening (by Region), SAM, $Million, 2021-2030
- Figure 109: U.S. Maternal Serum Screening Market (by Region), SOM, $Million, 2021-2030
- Figure 110: Northeast Region Maternal Serum Screening Market (by State), TAM, $Million, 2021-2030
- Figure 111: Northeast Region Maternal Serum Screening Market (by State), SAM, $Million, 2021-2030
- Figure 112: Northeast Region Maternal Serum Screening Market (by State), SOM, $Million, 2021-2030
- Figure 113: Midwest Region Maternal Serum Screening Market (by State), TAM, $Million, 2021-2030
- Figure 114: Midwest Region Maternal Serum Screening Market (by State), SAM, $Million, 2021-2030
- Figure 115: Midwest Region Maternal Serum Screening Market (by State), SOM, $Million, 2021-2030
- Figure 116: South Region Maternal Serum Screening Market (by State), TAM, $Million, 2021-2030
- Figure 117: South Region Maternal Serum Screening Market (by State), SAM, $Million, 2021-2030
- Figure 118: South Region Maternal Serum Screening Market (by State), SOM, $Million, 2021-2030
- Figure 119: West Region Maternal Serum Screening Market (by State), TAM, $Million, 2021-2030
- Figure 120: West Region Maternal Serum Screening Market (by State), SAM, $Million, 2021-2030
- Figure 121: West Region Maternal Serum Screening Market (by State), SOM, $Million, 2021-2030
- Figure 122: U.S. Prenatal Diagnostic Testing Market, $Million, 2021-2030
- Figure 123: U.S. Prenatal Diagnostic Testing Market (by Region), TAM, $Million, 2021-2030
- Figure 124: U.S. Prenatal Diagnostic Testing Market (by Region), SAM, $Million, 2021-2030
- Figure 125: U.S. Prenatal Diagnostic Testing Market (by Region), SOM, $Million, 2021-2030
- Figure 126: Northeast Region Prenatal Diagnostic Testing Market (by State), TAM, $Million, 2021-2030
- Figure 127: Northeast Region Prenatal Diagnostic Testing Market (by State), SAM, $Million, 2021-2030
- Figure 128: Northeast Region Prenatal Diagnostic Testing Market (by State), SOM, $Million, 2021-2030
- Figure 129: Midwest Region Prenatal Diagnostic Testing Market (by State), TAM, $Million, 2021-2030
- Figure 130: Midwest Region Prenatal Diagnostic Testing Market (by State), SAM, $Million, 2021-2030
- Figure 131: Midwest Region Prenatal Diagnostic Testing Market (by State), SOM, $Million, 2021-2030
- Figure 132: South Region Prenatal Diagnostic Testing Market (by State), TAM, $Million, 2021-2030
- Figure 133: South Region Prenatal Diagnostic Testing Market (by State), SAM, $Million, 2021-2030
- Figure 134: South Region Prenatal Diagnostic Testing Market (by State), SOM, $Million, 2021-2030
- Figure 135: West Region Prenatal Diagnostic Testing Market (by State), TAM, $Million, 2021-2030
- Figure 136: West Region Prenatal Diagnostic Testing Market (by State), SAM, $Million, 2021-2030
- Figure 137: West Region Prenatal Diagnostic Testing Market (by State), SOM, $Million, 2021-2030
- Figure 138: U.S. Women Health Laboratory Testing Market (by Reproductive Health and Infectious Diseases)
- Figure 139: U.S. Pregnancy and Ovulation Testing Market, $Million, 2021-2030
- Figure 140: U.S. Pregnancy and Ovulation Testing Market (by Region), TAM, $Million, 2021-2030
- Figure 141: U.S. Pregnancy and Ovulation Testing Market (by Region), SAM, $Million, 2021-2030
- Figure 142: U.S. Pregnancy and Ovulation Testing Market (by Region), SOM, $Million, 2021-2030
- Figure 143: Northeast Region Pregnancy and Ovulation Testing Market (by State), TAM, $Million, 2021-2030
- Figure 144: Northeast Region Pregnancy and Ovulation Testing Market (by State), SAM, $Million, 2021-2030
- Figure 145: Northeast Region Pregnancy and Ovulation Testing Market (by State), SOM, $Million, 2021-2030
- Figure 146: Midwest Region Pregnancy and Ovulation Testing Market (by State), TAM, $Million, 2021-2030
- Figure 147: Midwest Region Pregnancy and Ovulation Testing Market (by State), SAM, $Million, 2021-2030
- Figure 148: Midwest Region Pregnancy and Ovulation Testing Market (by State), SOM, $Million, 2021-2030
- Figure 149: South Region Pregnancy and Ovulation Testing Market (by State), TAM, $Million, 2021-2030
- Figure 150: South Region Pregnancy and Ovulation Testing Market (by State), SAM, $Million, 2021-2030
- Figure 151: South Region Pregnancy and Ovulation Testing Market (by State), SOM, $Million, 2021-2030
- Figure 152: West Region Pregnancy and Ovulation Testing Market (by State), TAM, $Million, 2021-2030
- Figure 153: West Region Pregnancy and Ovulation Testing Market (by State), SAM, $Million, 2021-2030
- Figure 154: West Region Pregnancy and Ovulation Testing Market (by State), SOM, $Million, 2021-2030
- Figure 155: U.S. HPV Testing Market, $Million, 2021-2030
- Figure 156: U.S. HPV Testing Market (by Region), TAM, $Million, 2021-2030
- Figure 157: U.S. HPV Testing Market (by Region), SAM, $Million, 2021-2030
- Figure 158: U.S. HPV Testing Market (by Region), SOM, $Million, 2021-2030
- Figure 159: Northeast Region HPV Testing Market (by State), TAM, $Million, 2021-2030
- Figure 160: Northeast Region HPV Testing Market (by State), SAM, $Million, 2021-2030
- Figure 161: Northeast Region HPV Testing Market (by State), SOM, $Million, 2021-2030
- Figure 162: Midwest Region HPV Testing Market (by State), TAM, $Million, 2021-2030
- Figure 163: Midwest Region HPV Testing Market (by State), SAM, $Million, 2021-2030
- Figure 164: Midwest Region HPV Testing Market (by State), SOM, $Million, 2021-2030
- Figure 165: South Region HPV Testing Market (by State), TAM, $Million, 2021-2030
- Figure 166: South Region HPV Testing Market (by State), SAM, $Million, 2021-2030
- Figure 167: South Region HPV Testing Market (by State), SOM, $Million, 2021-2030
- Figure 168: West Region HPV Testing Market (by State), TAM, $Million, 2021-2030
- Figure 169: West Region HPV Testing Market (by State), SAM, $Million, 2021-2030
- Figure 170: West Region HPV Testing Market (by State), SOM, $Million, 2021-2030
- Figure 171: U.S. PAP Smear Testing Market, $Million, 2021-2030
- Figure 172: U.S. PAP Smear Testing Market (by Region), TAM, $Million, 2021-2030
- Figure 173: U.S. PAP Smear Testing Market (by Region), SAM, $Million, 2021-2030
- Figure 174: U.S. PAP Smear Testing Market (by Region), SOM, $Million, 2021-2030
- Figure 175: Northeast Region PAP Smear Testing (by State), TAM, $Million, 2021-2030
- Figure 176: Northeast Region PAP Smear Testing (by State), SAM, $Million, 2021-2030
- Figure 177: Northeast Region PAP Smear Testing (by State), SOM, $Million, 2021-2030
- Figure 178: Midwest Region PAP Smear Testing (by State), TAM, $Million, 2021-2030
- Figure 179: Midwest Region PAP Smear Testing (by State), SAM, $Million, 2021-2030
- Figure 180: Midwest Region PAP Smear Testing (by State), SOM, $Million, 2021-2030
- Figure 181: South Region PAP Smear Testing (by State), TAM, $Million, 2021-2030
- Figure 182: South Region PAP Smear Testing (by State), SAM, $Million, 2021-2030
- Figure 183: South Region PAP Smear Testing (by State), SOM, $Million, 2021-2030
- Figure 184: West Region PAP Smear Testing (by State), TAM, $Million, 2021-2030
- Figure 185: West Region PAP Smear Testing (by State), SAM, $Million, 2021-2030
- Figure 186: West Region PAP Smear Testing (by State), SOM, $Million, 2021-2030
- Figure 187: U.S. HIV Testing Market, $Million, 2021-2030
- Figure 188: U.S. HIV Testing Market (by Region), TAM, $Million, 2021-2030
- Figure 189: U.S. HIV Testing Market (by Region), SAM, $Million, 2021-2030
- Figure 190: U.S. HIV Testing Market (by Region), SOM, $Million, 2021-2030
- Figure 191: Northeast Region HIV Testing Market (by State), TAM, $Million, 2021-2030
- Figure 192: Northeast Region HIV Testing Market (by State), SAM, $Million, 2021-2030
- Figure 193: Northeast Region HIV Testing Market (by State), SOM, $Million, 2021-2030
- Figure 194: Midwest Region HIV Testing Market (by State), TAM, $Million, 2021-2030
- Figure 195: Midwest Region HIV Testing Market (by State), SAM, $Million, 2021-2030
- Figure 196: Midwest Region HIV Testing Market (by State), SOM, $Million, 2021-2030
- Figure 197: South Region HIV Testing Market (by State), TAM, $Million, 2021-2030
- Figure 198: South Region HIV Testing Market (by State), SAM, $Million, 2021-2030
- Figure 199: South Region HIV Testing Market (by State), SOM, $Million, 2021-2030
- Figure 200: West Region HIV Testing Market (by State), TAM, $Million, 2021-2030
- Figure 201: West Region HIV Testing Market (by State), SAM, $Million, 2021-2030
- Figure 202: West Region HIV Testing Market (by State), SOM, $Million, 2021-2030
- Figure 203: U.S. CT/NG Testing Market, $Million, 2021-2030
- Figure 204: U.S. CT/NG Testing Market (by Region), TAM, $Million, 2021-2030
- Figure 205: U.S. CT/NG Testing Market (by Region), SAM, $Million, 2021-2030
- Figure 206: U.S. CT/NG Testing Market (by Region), SOM, $Million, 2021-2030
- Figure 207: Northeast Region CT/NG Testing Market (by State), TAM, $Million, 2021-2030
- Figure 208: Northeast Region CT/NG Testing Market (by State), SAM, $Million, 2021-2030
- Figure 209: Northeast Region CT/NG Testing Market (by State), SOM, $Million, 2021-2030
- Figure 210: Midwest Region CT/NG Testing Market (by State), TAM, $Million, 2021-2030
- Figure 211: Midwest Region CT/NG Testing Market (by State), SAM, $Million, 2021-2030
- Figure 212: Midwest Region CT/NG Testing Market (by State), SOM, $Million, 2021-2030
- Figure 213: South Region CT/NG Testing Market (by State), TAM, $Million, 2021-2030
- Figure 214: South Region CT/NG Testing Market (by State), SAM, $Million, 2021-2030
- Figure 215: South Region CT/NG Testing Market (by State), SOM, $Million, 2021-2030
- Figure 216: West Region CT/NG Testing Market (by State), TAM, $Million, 2021-2030
- Figure 217: West Region CT/NG Testing Market (by State), SAM, $Million, 2021-2030
- Figure 218: West Region CT/NG Testing Market (by State), SOM, $Million, 2021-2030
- Figure 219: U.S. Preimplantation Genetic Testing Market, $Million, 2021-2030
- Figure 220: U.S. Preimplantation Genetic Testing Market (by Region), TAM, $Million, 2021-2030
- Figure 221: U.S. Preimplantation Genetic Testing Market (by Region), SAM, $Million, 2021-2030
- Figure 222: U.S. Preimplantation Genetic Testing (by Region), SOM, $Million, 2021-2030
- Figure 223: Northeast Region Preimplantation Genetic Testing Market (by State), TAM, $Million, 2021-2030
- Figure 224: Northeast Region Preimplantation Genetic Testing Market (by State), SAM, $Million, 2021-2030
- Figure 225: Northeast Region Preimplantation Genetic Testing Market (by State), SOM, $Million, 2021-2030
- Figure 226: Midwest Region Preimplantation Genetic Testing Market (by State), TAM, $Million, 2021-2030
- Figure 227: Midwest Region Preimplantation Genetic Testing Market (by State), SAM, $Million, 2021-2030
- Figure 228: Midwest Region Preimplantation Genetic Testing Market (by State), SOM, $Million, 2021-2030
- Figure 229: South Region Preimplantation Genetic Testing Market (by State), TAM, $Million, 2021-2030
- Figure 230: South Region Preimplantation Genetic Testing Market (by State), SAM, $Million, 2021-2030
- Figure 231: South Region Preimplantation Genetic Testing Market (by State), SOM, $Million, 2021-2030
- Figure 232: West Region Preimplantation Genetic Testing Market (by State), TAM, $Million, 2021-2030
- Figure 233: West Region Preimplantation Genetic Testing Market (by State), SAM, $Million, 2021-2030
- Figure 234: West Region Preimplantation Genetic Testing Market (by State), SOM, $Million, 2021-2030
- Figure 235: U.S. Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market, $Million, 2021-2030
- Figure 236: U.S. Sexually Transmitted Infection (Syphilis, Gonorrhea, Chlamydia) Market (by Region), TAM, $Million, 2021-2030
- Figure 237: U.S. Sexually Transmitted Infection (Syphilis, Gonorrhea, Chlamydia) Market (by Region), SAM, $Million, 2021-2030
- Figure 238: U.S. Sexually Transmitted Infection (Syphilis, Gonorrhea, Chlamydia) Market (by Region), SOM, $Million, 2021-2030
- Figure 239: Northeast Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
- Figure 240: Northeast Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SAM, $Million, 2021-2030
- Figure 241: Northeast Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SOM, $Million, 2021-20300
- Figure 242: Midwest Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
- Figure 243: Midwest Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SAM, $Million, 2021-2030
- Figure 244: Midwest Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SOM, $Million, 2021-2030
- Figure 245: South Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
- Figure 246: South Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SAM, $Million, 2021-2030
- Figure 247: South Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SOM, $Million, 2021-2030
- Figure 248: West Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
- Figure 249: West Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SAM, $Million, 2021-2030
- Figure 250: West Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
- Figure 251: U.S. Herpes Simplex Virus (HSV) Market, $Million, 2021-2030
- Figure 252: U.S. Herpes Simplex Virus (HSV) Market (by Region), TAM, $Million, 2021-2030
- Figure 253: U.S. Herpes Simplex Virus (HSV) Market (by Region), SAM, $Million, 2021-2030
- Figure 254: U.S. Herpes Simplex Virus (HSV) Market (by Region), SOM, $Million, 2021-2030
- Figure 255: Northeast Region Herpes Simplex Virus (HSV) Market (by State), TAM, $Million, 2021-2030
- Figure 256: Northeast Region Northeast Region Herpes Simplex Virus (HSV) Market (by State), SAM, $Million, 2021-2030
- Figure 257: Northeast Region Northeast Region Herpes Simplex Virus (HSV) Market (by State), SOM, $Million, 2021-2030
- Figure 258: Midwest Region Herpes Simplex Virus (HSV) Market (by State), TAM, $Million, 2021-2030
- Figure 259: Midwest Region Herpes Simplex Virus (HSV) Market (by State), SAM, $Million, 2021-2030
- Figure 260: Midwest Region Herpes Simplex Virus (HSV) Market (by State), SOM, $Million, 2021-2030
- Figure 261: South Region Herpes Simplex Virus (HSV) Market (by State), TAM, $Million, 2021-2030
- Figure 262: South Region Herpes Simplex Virus (HSV) Market (by State), SAM, $Million, 2021-2030
- Figure 263: South Region Herpes Simplex Virus (HSV) Market (by State), SOM, $Million, 2021-2030
- Figure 264: West Region Herpes Simplex Virus (HSV) Market (by State), TAM, $Million, 2021-2030
- Figure 265: West Region Herpes Simplex Virus (HSV) Market (by State), SAM, $Million, 2021-2030
- Figure 266: West Region Herpes Simplex Virus (HSV) Market (by State), SOM, $Million, 2021-2030
- Figure 267: U.S. Hepatitis Market, $Million, 2021-2030
- Figure 268: U.S. Hepatitis Market (by Region), TAM, $Million, 2021-2030
- Figure 269: U.S. Hepatitis Market (by Region), SAM, $Million, 2021-2030
- Figure 270: U.S. Hepatitis Market (by Region), SOM, $Million, 2021-2030
- Figure 271: Northeast Region Hepatitis Market (by State), TAM, $Million, 2021-2030
- Figure 272: Northeast Region Hepatitis Market (by State), SAM, $Million, 2021-2030
- Figure 273: Northeast Region Hepatitis Market (by State), SOM, $Million, 2021-2030
- Figure 274: Midwest Region Hepatitis Market (by State), TAM, $Million, 2021-2030
- Figure 275: Midwest Region Hepatitis Market (by State), SAM, $Million, 2021-2030
- Figure 276: Midwest Region Hepatitis Market (by State), SOM, $Million, 2021-2030
- Figure 277: South Region Hepatitis Market (by State), TAM, $Million, 2021-2030
- Figure 278: South Region Hepatitis Market (by State), SAM, $Million, 2021-2030
- Figure 279: South Region Hepatitis Market (by State), SOM, $Million, 2021-2030
- Figure 280: West Region Hepatitis Market (by State), TAM, $Million, 2021-2030
- Figure 281: West Region Hepatitis Market (by State), SAM, $Million, 2021-2030
- Figure 282: West Region Hepatitis Market (by State), SOM, $Million, 2021-2030
- Figure 283: U.S. Vaginal Infections Market, $Million, 2021-2030
- Figure 284: U.S. Vaginal Infections Market (by Region), TAM, $Million, 2021-2030
- Figure 285: U.S. Vaginal Infections Market (by Region), SAM, $Million, 2021-2030
- Figure 286: U.S. Vaginal Infections Market (by Region), SOM, $Million, 2021-2030
- Figure 287: Northeast Region Vaginal Infections Market (by State), TAM, $Million, 2021-2030
- Figure 288: Northeast Region Vaginal Infections Market (by State), SAM, $Million, 2021-2030
- Figure 289: Northeast Region Vaginal Infections Market (by State), SOM, $Million, 2021-2030
- Figure 290: Midwest Region Vaginal Infections Market (by State), TAM, $Million, 2021-2030
- Figure 291: Midwest Region Vaginal Infections Market (by State), SAM, $Million, 2021-2030
- Figure 292: Midwest Region Vaginal Infections Market (by State), SOM, $Million, 2021-2030
- Figure 293: South Region Vaginal Infections Market (by State), TAM, $Million, 2021-2030
- Figure 294: South Region Vaginal Infections Market (by State), SAM, $Million, 2021-2030
- Figure 295: South Region Vaginal Infections Market (by State), SOM, $Million, 2021-2030
- Figure 296: West Region Vaginal Infections Market (by State), TAM, $Million, 2021-2030
- Figure 297: West Region Vaginal Infections Market (by State), SAM, $Million, 2021-2030
- Figure 298: West Region Vaginal Infections Market (by State), SOM, $Million, 2021-2030
- Figure 299: U.S. Obstetrics and Gynecology Market (by Region), TAM, $Million, 2021-2030
- Figure 300: U.S. Obstetrics and Gynecology Market (by Region), SAM, $Million, 2021-2030
- Figure 301: U.S. Obstetrics and Gynecology Testing (by Region), SOM, $Million, 2021-2030
- Figure 302: Northeast Region Obstetrics and Gynecology Market (by State), TAM, $Million, 2021-2030
- Figure 303: Northeast Region Obstetrics and Gynecology Market (by State), SAM, $Million, 2021-2030
- Figure 304: Northeast Region Obstetrics and Gynecology Market (by State), SOM, $Million, 2021-2030
- Figure 305: Midwest Region Obstetrics and Gynecology (by State), TAM, $Million, 2021-2030
- Figure 306: Midwest Region Obstetrics and Gynecology Market (by State), SAM, $Million, 2021-2030
- Figure 307: Midwest Region Obstetrics and Gynecology Market (by State), SOM, $Million, 2021-2030
- Figure 308: South Region Obstetrics and Gynecology Market (by State), TAM, $Million, 2021-2030
- Figure 309: South Region Obstetrics and Gynecology Market (by State), SAM, $Million, 2021-2030
- Figure 310: South Region Obstetrics and Gynecology Market (by State), SOM, $Million, 2021-2030
- Figure 311: West Region Obstetrics and Gynecology Market (by State), TAM, $Million, 2021-2030
- Figure 312: West Region Obstetrics and Gynecology Market (by State), SAM, $Million, 2021-2030
- Figure 313: West Region Obstetrics and Gynecology Market (by State), SOM, $Million, 2021-2030
- List of Tables
- Table 1: Key Questions Answered in the Report
- Table 2: U.S. Women Health Laboratory Testing Market, Approach Note
- Table 3: Cervical Cancer Market, Approach Note
- Table 4: Carrier Screening Market, Approach Note
- Table 5: Non-Invasive Prenatal Testing Market, Approach Note
- Table 6: HPV Testing Market, Approach Note
- Table 7: PAP Smear Testing Market, Approach Note
- Table 8: Sexually Transmitted Infections Market, Approach Note
- Table 9: Vaginal Infections Market, Approach Note
- Table 10: HRSA-Supported Women's Preventive Services Guidelines: Current and Updated Guidelines
- Table 11: Estimated Down Syndrome Birth Prevalence Per 1,000 Births at Different Maternal Ages
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook